Recombinant Anti-HER2 x Anti-HER3 Bispecific Antibody (Diabody-Fc) is a fusion protein of two diabodies connected together by an Fc region. In a diabody, the two scFvs with short linkers are from anti-HER2 and anti-HER3 antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to the Fc fragment, which results in 2+2 antigen-binding valency and exerts Fc-mediated functions or just extends the half-life. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.
Constant Domain-extended Bispecific Fragments
FuncS; Promising therapeutic agent
Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors
ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; human epidermal growth factor receptor 2; neuro/glioblastoma derived oncogene homolog; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email